Christian Koenecke

May 1, 2024 | nature.com | Francis Ayuk |Eva-Maria Wagner-Drouet |Christian Koenecke

AbstractAlthough most patients with chronic graft-versus-host disease (cGVHD) show initial response to first-line therapy, long-term clinically meaningful success of first-line treatment remains rare. In a prospective multicentre phase II trial in 6 German centers, patients with newly diagnosed moderate or severe cGVHD received prednisone and everolimus for 12 months followed by a 1-year follow-up period.